Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Lung cancer remains a challenging disease with limited curative options.
• Gene therapy, particularly the herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) method, is being explored as an alternative treatment strategy.
• Previous studies have investigated HSV-TK/GCV for lung cancer, but a systematic comparison across different non-small cell lung cancer (NSCLC) subtypes is lacking.

Purpose of the Study:

• To evaluate the efficacy of adenovirus-mediated HSV-TK/GCV gene therapy in vitro and in vivo across different NSCLC subtypes including adenocarcinoma, squamous cell lung cancer, and large cell lung cancer.
• To assess the efficiency of gene transfer using adenovirus vectors in various NSCLC cell lines.
• To investigate the role of the bystander effect in the therapeutic outcome.

Main Methods:

• Utilized an adenovirus vector carrying a fusion gene of HSV-TK and green fluorescent protein (GFP) for gene transfer.
• Tested the efficacy of HSV-TK/GCV therapy on established NSCLC cell lines representing adenocarcinoma, squamous cell lung cancer, and large cell lung cancer.
• Evaluated treatment response in subcutaneous tumor models derived from these NSCLC subtypes.

Main Results:

• Adenoviruses demonstrated efficient gene transfer capabilities across all tested NSCLC types.
• Adenocarcinoma and large cell lung cancer cell lines were responsive to HSV-TK/GCV therapy.
• One squamous cell carcinoma cell line showed resistance to the treatment, highlighting potential subtype-specific variations.
• The bystander effect was identified as a critical factor in the overall success of the gene therapy.
• Adenovirus-mediated HSV-TK/GCV gene therapy effectively treated subcutaneous tumors of all three NSCLC types.

Conclusions:

• Adenovirus-mediated HSV-TK/GCV gene therapy is a potentially effective treatment modality for human NSCLC.
• The efficacy of this gene therapy can vary among NSCLC subtypes, with squamous cell carcinoma showing potential resistance.
• The bystander effect plays a significant role in the therapeutic efficacy of HSV-TK/GCV gene therapy.
• Further research using primary lung cancer cells and orthotopic models is warranted to validate these findings.